EA201200999A1 - Способы лечения рака молочной железы - Google Patents
Способы лечения рака молочной железыInfo
- Publication number
- EA201200999A1 EA201200999A1 EA201200999A EA201200999A EA201200999A1 EA 201200999 A1 EA201200999 A1 EA 201200999A1 EA 201200999 A EA201200999 A EA 201200999A EA 201200999 A EA201200999 A EA 201200999A EA 201200999 A1 EA201200999 A1 EA 201200999A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- breast cancer
- methods
- treatment breast
- treatment
- progastrin
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 3
- 101800000285 Big gastrin Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее описание относится к способам лечения и профилактики рака молочной железы или рецидива рака молочной железы с помощью композиций, содержащих антитела к прогастрину.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29361210P | 2010-01-08 | 2010-01-08 | |
| PCT/EP2011/000048 WO2011083090A2 (en) | 2010-01-08 | 2011-01-07 | Methods for treating breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201200999A1 true EA201200999A1 (ru) | 2013-02-28 |
| EA025329B1 EA025329B1 (ru) | 2016-12-30 |
Family
ID=43607948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201200999A EA025329B1 (ru) | 2010-01-08 | 2011-01-07 | Способы профилактики или предотвращения рецидивов или лечения рака молочной железы |
| EA201200998A EA023722B1 (ru) | 2010-01-08 | 2011-01-07 | ПРИМЕНЕНИЕ АНТИТЕЛА К ЧЕЛОВЕЧЕСКОМУ ПРОГАСТРИНУ (hPG) ДЛЯ ЛЕЧЕНИЯ РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201200998A EA023722B1 (ru) | 2010-01-08 | 2011-01-07 | ПРИМЕНЕНИЕ АНТИТЕЛА К ЧЕЛОВЕЧЕСКОМУ ПРОГАСТРИНУ (hPG) ДЛЯ ЛЕЧЕНИЯ РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9487582B2 (ru) |
| EP (2) | EP2542583B8 (ru) |
| JP (2) | JP6134141B2 (ru) |
| KR (2) | KR101438362B1 (ru) |
| CN (2) | CN102933603B (ru) |
| AU (2) | AU2011204653B2 (ru) |
| BR (2) | BR112012016742A2 (ru) |
| CA (2) | CA2786435C (ru) |
| EA (2) | EA025329B1 (ru) |
| ES (2) | ES2657246T3 (ru) |
| NZ (2) | NZ601591A (ru) |
| PL (2) | PL2542583T3 (ru) |
| SG (2) | SG182334A1 (ru) |
| WO (2) | WO2011083091A2 (ru) |
| ZA (2) | ZA201205003B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7854932B2 (en) | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US8136651B2 (en) * | 2007-12-14 | 2012-03-20 | The Procter & Gamble Company | Method and apparatus for orienting articles |
| AU2011284908B2 (en) * | 2010-07-26 | 2015-05-21 | Centre National De La Recherche Scientifique (Cnrs) | Methods and compositions for liver cancer therapy |
| EP4477269A3 (en) | 2015-09-20 | 2025-03-19 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use |
| EA037027B1 (ru) | 2015-12-31 | 2021-01-27 | Прогастрин Э Кансер С.А Р.Л. | Применение и способ для профилактики или лечения рака желудка с использованием композиции, содержащей моноклональное прогастринсвязывающее антитело |
| CN108780091A (zh) * | 2015-12-31 | 2018-11-09 | 普莱戈斯瑞恩癌症有限责任公司 | 用于检测和治疗卵巢癌的组合物和方法 |
| SG11201804629XA (en) * | 2015-12-31 | 2018-07-30 | Syncerus S A R L | Compositions and methods for assessing the risk of cancer occurrence |
| BR112018013272A2 (pt) * | 2015-12-31 | 2018-12-11 | Progastrine Et Cancers S A R L | composições e métodos para detectar e tratar câncer esofágico |
| KR20180081675A (ko) * | 2017-01-06 | 2018-07-17 | 주식회사 레모넥스 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
| CN110945025B (zh) | 2017-03-30 | 2023-11-03 | Ecs前胃泌素股份有限公司 | 用于检测前列腺癌的组合物和方法 |
| CA3058270C (en) | 2017-03-30 | 2023-07-18 | Ecs-Progastrin Sa | Compositions and methods for detecting lung cancer |
| EP3624841A4 (en) * | 2017-06-15 | 2021-01-27 | Cancer Advances, Inc., | COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER |
| WO2019055776A2 (en) | 2017-09-14 | 2019-03-21 | Rosser Charles | COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING CXCL1 FUNCTION |
| KR102461238B1 (ko) * | 2017-12-05 | 2022-11-01 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료 |
| JP7338128B2 (ja) | 2017-12-08 | 2023-09-05 | イー、シー、エス、ビオトラッカー、エス、エー、アール、エル | 癌診断における放射性標識プロガストリン |
| WO2019145537A1 (en) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combination of progastrin detection with other cancer biomarkers in cancer diagnosis |
| CN112368579B (zh) | 2018-02-27 | 2024-05-03 | Ecs前胃泌素股份有限公司 | 作为生物标记物的前胃泌素用于免疫疗法 |
| WO2019177854A1 (en) * | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
| CN108864255B (zh) * | 2018-06-21 | 2022-01-04 | 天津医科大学肿瘤医院 | 一种乳腺癌干细胞特异性结合多肽及其在制备治疗乳腺癌药物中的应用 |
| US11292832B2 (en) | 2019-01-28 | 2022-04-05 | Charles J. Rosser | Compositions and methods for treatment of diseases involving CXCL1 function |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| NZ511550A (en) | 1997-05-12 | 2005-03-24 | Aphton Corp | CCK-B/gastrin receptor inhibitors for the treatment of tumors |
| EP1261371A4 (en) | 2000-02-25 | 2005-04-13 | Univ California | THERAPY DIRECTED ON THE MEMBRANE RECEPTOR OF ESTROGENES IN BREAST CANCER |
| FR2846426B1 (fr) | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| DK1794586T3 (da) | 2004-09-22 | 2013-05-13 | Cancer Advances Inc | Monoklonale antistoffer til progastrin |
| US20100209426A1 (en) * | 2006-05-22 | 2010-08-19 | Inserm (Institut National De La Sante Et De La Rec Herche Medicale) | Inhibitors of progastrin-induced repression of icat for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/tcf-mediated transcriptional pathway is constitutively active |
| JPWO2008032876A1 (ja) | 2006-09-15 | 2010-01-28 | 学校法人東海大学 | Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法 |
| US20100092476A1 (en) | 2006-11-17 | 2010-04-15 | Hanash Samir M | Pancreatic cancer biomarkers |
| US7854932B2 (en) | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| JP2010540460A (ja) | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ，インク． | ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療 |
| UA106771C2 (ru) * | 2009-10-16 | 2014-10-10 | Ле Лаборатуар Сервьє | Моноклональные антитела к прогастрину и их применение |
-
2011
- 2011-01-04 US US12/984,522 patent/US9487582B2/en not_active Expired - Fee Related
- 2011-01-04 US US12/984,509 patent/US8900588B2/en not_active Expired - Fee Related
- 2011-01-07 WO PCT/EP2011/000049 patent/WO2011083091A2/en not_active Ceased
- 2011-01-07 EP EP11700068.7A patent/EP2542583B8/en active Active
- 2011-01-07 NZ NZ601591A patent/NZ601591A/en not_active IP Right Cessation
- 2011-01-07 SG SG2012049177A patent/SG182334A1/en unknown
- 2011-01-07 EA EA201200999A patent/EA025329B1/ru not_active IP Right Cessation
- 2011-01-07 ES ES11700115.6T patent/ES2657246T3/es active Active
- 2011-01-07 KR KR1020127020835A patent/KR101438362B1/ko not_active Expired - Fee Related
- 2011-01-07 NZ NZ601588A patent/NZ601588A/en not_active IP Right Cessation
- 2011-01-07 AU AU2011204653A patent/AU2011204653B2/en not_active Ceased
- 2011-01-07 PL PL11700068T patent/PL2542583T3/pl unknown
- 2011-01-07 EP EP11700115.6A patent/EP2542584B8/en active Active
- 2011-01-07 BR BR112012016742A patent/BR112012016742A2/pt not_active Application Discontinuation
- 2011-01-07 JP JP2012547495A patent/JP6134141B2/ja not_active Expired - Fee Related
- 2011-01-07 JP JP2012547494A patent/JP5572718B2/ja not_active Expired - Fee Related
- 2011-01-07 CN CN201180013036.8A patent/CN102933603B/zh not_active Expired - Fee Related
- 2011-01-07 PL PL11700115T patent/PL2542584T3/pl unknown
- 2011-01-07 ES ES11700068.7T patent/ES2657245T3/es active Active
- 2011-01-07 BR BR112012016820A patent/BR112012016820A2/pt not_active IP Right Cessation
- 2011-01-07 SG SG2012049136A patent/SG182331A1/en unknown
- 2011-01-07 WO PCT/EP2011/000048 patent/WO2011083090A2/en not_active Ceased
- 2011-01-07 CA CA2786435A patent/CA2786435C/en not_active Expired - Fee Related
- 2011-01-07 CA CA2786479A patent/CA2786479C/en not_active Expired - Fee Related
- 2011-01-07 KR KR1020127020871A patent/KR101468397B1/ko not_active Expired - Fee Related
- 2011-01-07 AU AU2011204654A patent/AU2011204654B2/en not_active Ceased
- 2011-01-07 CN CN201180013038.7A patent/CN102892784B/zh not_active Expired - Fee Related
- 2011-01-07 EA EA201200998A patent/EA023722B1/ru not_active IP Right Cessation
-
2012
- 2012-07-04 ZA ZA2012/05003A patent/ZA201205003B/en unknown
- 2012-07-04 ZA ZA2012/05004A patent/ZA201205004B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201200999A1 (ru) | Способы лечения рака молочной железы | |
| EA201201000A1 (ru) | Способы лечения колоректального рака | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
| EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| IN2014KN00848A (ru) | ||
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
| MY173839A (en) | Cd37-binding molecules and immunoconjugates thereof | |
| EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
| EA201390274A1 (ru) | Борсодержащие малые молекулы | |
| EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
| EA201291194A1 (ru) | Индолы | |
| MX381456B (es) | Regulador de ph de transduccion. | |
| MX2013004897A (es) | Anticuerpos y composiciones anti-her3. | |
| MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| MX347020B (es) | Anticuerpo contra el csf-1r. | |
| EA201490850A1 (ru) | Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
| EA201290642A1 (ru) | Соединения и способы | |
| EA201370071A1 (ru) | Способы и композиции для лечения рака легких | |
| EA201170288A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |